C4 Therapeutics ( (CCCC) ) has shared an update.
C4 Therapeutics has appointed Paige Mahaney, Ph.D., as the new Chief Scientific Officer, succeeding Dr. Stewart Fisher, who will retire but continue as a senior scientific advisor until the end of 2024. Dr. Mahaney, with over 25 years in pharmaceutical and biotech sectors, brings extensive experience in drug discovery and clinical portfolio expansion, which is expected to further advance C4T’s mission in targeted protein degradation science. Her leadership aims to leverage C4T’s innovative TORPEDO® platform, enhancing the development of new therapeutic approaches for challenging diseases.
For detailed information about CCCC stock, go to TipRanks’ Stock Analysis page.
